Press Release - September 14, 2022

Streck Announces Series B Investment in Ceres Nanosciences

La Vista, Nebraska — September 14, 2022 – Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres’ Nanotrap® technology platform.

“Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers,” said Ceres CEO Ross Dunlap. “We are thrilled to have Streck’s support and guidance in this next, exciting phase of our growth.”

Announcement_Graphics_FB_1200x630.jpg

This investment builds on the pre-existing partnership between Ceres and Streck, which has produced the Streck® Viral Extraction Kit, powered by Nanotrap technology, and a global distribution agreement covering Nanotrap particles for virus capture and concentration from wastewater samples.

“Ceres has a fantastic reputation for delivering innovative, high-quality products,” said Matthew Kreifels, Vice President of Sales. “We look forward to the positive impacts this partnership will have and working closely with their team to maximize the company’s impacts in the public health and diagnostics arenas.”

Streck will join Series A investor GreyBird Ventures on Ceres’ Board of Directors.

“We are very happy with our investment in Ceres and are pleased that Streck has joined us," said Tom Miller, GreyBird Ventures Co-Founder and Chair of Ceres’ Board. “A world-class company like Streck as a strategic partner, coupled with a Ceres team that has demonstrated the ability to solve some of the most difficult problems in health care diagnostics, is a clear catalyst for accelerated growth.” 

 

About Ceres Nanosciences, Inc.

Ceres Nanosciences is a privately held company, located in Northern Virginia, focused on incorporating its proprietary Nanotrap® particle technology into a range of diagnostic and research use products and workflows. Nanotrap® particles capture, concentrate, and preserve low abundance analytes from biological samples, enabling early and accurate detection of diseases. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, the Centers for Disease Control and Prevention, and the Commonwealth of Virginia.

 

Ceres Nanosciences Press Contact:

Ross M. Dunlap

Ceres Nanosciences, Inc

1.800.615.0418 ext. 202

rdunlap@ceresnano.com

About Streck, Inc.

Established in 1971, Streck develops and manufactures products in hematology, immunology, molecular diagnostics, cell stabilization, infectious diseases, and urinalysis for clinical and research laboratories. Streck’s passion for innovation, quality and service are what makes the organization a world leader in the development of quality control and diagnostic products helping laboratories ensure accurate and timely results for patients.

Streck Press Contact:

Matthew Kreifels

Streck, Inc.

1.800.843.0912

mkreifels@streck.com